XOMA Corporation Annual report pursuant to Section 13 and 15(d)

Royalty and Commercial Payment Purchase Agreements (Tables)

Royalty and Commercial Payment Purchase Agreements (Tables)

12 Months Ended

Dec. 31, 2021

Royalty and Commercial Payment Purchase Agreements

Summary of Acquisition of Royalty Rights

The following table summarizes the long-term royalty receivable activities including acquisitions of royalty rights, commercial payment rights and cash receipts for achievement of contractual milestones during the years ended December 31, 2021 and 2020 (in thousands):


Balance at January 1, 2020	$	34,375
Acquisition of royalty rights:
Bioasis		1,200
Cash receipts for achievement of contractual milestones:
Agenus		(1,000)
Balance at December 31, 2020		34,575
Acquisition of royalty and commercial payment rights:
Viracta		13,500
Kuros		7,000
Affitech		14,000
Balance at December 31, 2021	$	69,075